![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, March 07, 2015 6:38:28 AM
From seeking alpha:
But our research into Dr. Frost's background shows that while he has had some successes over his forty years as a pharma executive, his investment acumen leaves much to be desired. In fact, looking over his recent investment record, we find that he invested heavily in a fraudulent Chinese company and in numerous other pharmaceutical companies whose shares have subsequently fallen dramatically. Given Dr. Frost's flawed investment record, we think it is rather odd that the market would assign a nearly billion dollar premium to Opko's valuation merely due to Dr. Frost's repeated share purchases. If anything, investors should apply a discount to Opko's shares, given Frost's questionable public investing track record.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM